OC
MRTX

Oppenheimer & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Oppenheimer & Co’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,000
Closed -$293K – 1613
2021
Q4 		$293K Sell
2,000
-35
-2% -$5.43K 0.01% 1233
2021
Q3 		$360K Hold
2,035
– – 0.01% 1145
2021
Q2 		$329K Hold
2,035
– – 0.01% 1201
2021
Q1 		$349K Hold
2,035
– – 0.01% 1106
2020
Q4 		$447K Buy
2,035
+35
+2% +$7.57K 0.01% 938
2020
Q3 		$332K Hold
2,000
– – 0.01% 950
2020
Q2 		$228K Buy
+2,000
New +$194K 0.01% 1065
2015
Q3 		– Sell
-11,001
Closed -$346K – 1480
2015
Q2 		$346K Buy
+11,001
New +$324K 0.01% 1041

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Oppenheimer & Co's MRTX Position: Q1 2022 in Review

Oppenheimer & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 2,000 shares — an estimated $293K sold.

Oppenheimer & Co first reported a position in MRTX in Q2 2015 and held it in 8 quarters. The position peaked at $447K in Q4 2020. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • Oppenheimer & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 2,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $293K.
  • Oppenheimer & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2015 and held it in 8 quarters.
  • Oppenheimer & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $447K in Q4 2020.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Oppenheimer & Co's 13F filing for Q1 2022, filed 12 May 2022.